CGON Non Current Assets Total vs Cash Analysis

CGON Stock   34.75  0.65  1.91%   
CG Oncology, financial indicator trend analysis is way more than just evaluating CG Oncology, Common prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CG Oncology, Common is a good investment. Please check the relationship between CG Oncology, Non Current Assets Total and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Non Current Assets Total vs Cash

Non Current Assets Total vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CG Oncology, Common Non Current Assets Total account and Cash. At this time, the significance of the direction appears to have pay attention.
The correlation between CG Oncology,'s Non Current Assets Total and Cash is -0.87. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Cash in the same time period over historical financial statements of CG Oncology, Common, assuming nothing else is changed. The correlation between historical values of CG Oncology,'s Non Current Assets Total and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of CG Oncology, Common are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Current Assets Total i.e., CG Oncology,'s Non Current Assets Total and Cash go up and down completely randomly.

Correlation Coefficient

-0.87
Relationship DirectionNegative 
Relationship StrengthSignificant

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Cash

Cash refers to the most liquid asset of CG Oncology, Common, which is listed under current asset account on CG Oncology, Common balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from CG Oncology, customers. The amounts must be unrestricted with restricted cash listed in a different CG Oncology, account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.
Most indicators from CG Oncology,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CG Oncology, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
As of the 30th of November 2024, Sales General And Administrative To Revenue is likely to grow to 50.96, while Selling General Administrative is likely to drop about 7.7 M.
 2010 2022 2023 2024 (projected)
Interest Expense451K1K6.9M7.2M
Depreciation And Amortization10K15K17K15.4K

CG Oncology, fundamental ratios Correlations

-0.820.980.961.00.97-0.720.37-0.940.85-0.510.850.83-0.991.00.76-0.84-0.950.980.360.9-0.38-0.950.970.981.0
-0.82-0.88-0.68-0.83-0.70.94-0.820.94-0.910.9-1.0-1.00.74-0.81-0.351.00.94-0.72-0.74-0.930.830.95-0.7-0.69-0.81
0.98-0.880.890.990.9-0.730.51-0.940.94-0.630.890.88-0.930.970.61-0.89-0.950.920.530.97-0.53-0.960.90.940.98
0.96-0.680.890.951.0-0.650.14-0.880.67-0.30.730.7-0.990.970.91-0.71-0.891.00.090.75-0.16-0.871.00.970.96
1.0-0.830.990.950.96-0.720.39-0.940.86-0.530.860.84-0.981.00.74-0.85-0.950.970.390.92-0.41-0.950.960.981.0
0.97-0.70.91.00.96-0.660.18-0.890.7-0.330.750.72-1.00.980.89-0.73-0.911.00.130.78-0.19-0.891.00.980.97
-0.720.94-0.73-0.65-0.72-0.66-0.750.91-0.720.84-0.95-0.950.68-0.71-0.410.940.89-0.66-0.56-0.770.750.89-0.66-0.58-0.72
0.37-0.820.510.140.390.18-0.75-0.590.74-0.990.780.8-0.240.35-0.24-0.8-0.570.210.940.69-1.0-0.610.180.20.36
-0.940.94-0.94-0.88-0.94-0.890.91-0.59-0.850.71-0.97-0.950.91-0.94-0.640.961.0-0.9-0.49-0.910.61.0-0.89-0.86-0.94
0.85-0.910.940.670.860.7-0.720.74-0.85-0.810.90.9-0.750.830.3-0.91-0.860.730.790.99-0.75-0.890.70.770.84
-0.510.9-0.63-0.3-0.53-0.330.84-0.990.71-0.81-0.87-0.890.39-0.490.080.890.7-0.36-0.92-0.780.990.73-0.33-0.35-0.5
0.85-1.00.890.730.860.75-0.950.78-0.970.9-0.871.0-0.790.840.43-1.0-0.960.770.680.93-0.78-0.970.750.730.85
0.83-1.00.880.70.840.72-0.950.8-0.950.9-0.891.0-0.760.820.38-1.0-0.950.740.710.92-0.81-0.960.720.710.82
-0.990.74-0.93-0.99-0.98-1.00.68-0.240.91-0.750.39-0.79-0.76-0.99-0.850.770.93-1.0-0.21-0.820.250.91-1.0-0.99-0.99
1.0-0.810.970.971.00.98-0.710.35-0.940.83-0.490.840.82-0.990.78-0.83-0.950.990.330.89-0.36-0.950.980.981.0
0.76-0.350.610.910.740.89-0.41-0.24-0.640.30.080.430.38-0.850.78-0.39-0.660.87-0.330.410.23-0.620.890.820.77
-0.841.0-0.89-0.71-0.85-0.730.94-0.80.96-0.910.89-1.0-1.00.77-0.83-0.390.95-0.75-0.71-0.930.810.96-0.73-0.72-0.83
-0.950.94-0.95-0.89-0.95-0.910.89-0.571.0-0.860.7-0.96-0.950.93-0.95-0.660.95-0.91-0.48-0.920.581.0-0.91-0.88-0.95
0.98-0.720.921.00.971.0-0.660.21-0.90.73-0.360.770.74-1.00.990.87-0.75-0.910.170.81-0.22-0.91.00.990.98
0.36-0.740.530.090.390.13-0.560.94-0.490.79-0.920.680.71-0.210.33-0.33-0.71-0.480.170.72-0.95-0.530.130.220.35
0.9-0.930.970.750.920.78-0.770.69-0.910.99-0.780.930.92-0.820.890.41-0.93-0.920.810.72-0.71-0.940.780.830.9
-0.380.83-0.53-0.16-0.41-0.190.75-1.00.6-0.750.99-0.78-0.810.25-0.360.230.810.58-0.22-0.95-0.710.62-0.19-0.22-0.37
-0.950.95-0.96-0.87-0.95-0.890.89-0.611.0-0.890.73-0.97-0.960.91-0.95-0.620.961.0-0.9-0.53-0.940.62-0.89-0.87-0.95
0.97-0.70.91.00.961.0-0.660.18-0.890.7-0.330.750.72-1.00.980.89-0.73-0.911.00.130.78-0.19-0.890.980.97
0.98-0.690.940.970.980.98-0.580.2-0.860.77-0.350.730.71-0.990.980.82-0.72-0.880.990.220.83-0.22-0.870.980.98
1.0-0.810.980.961.00.97-0.720.36-0.940.84-0.50.850.82-0.991.00.77-0.83-0.950.980.350.9-0.37-0.950.970.98
Click cells to compare fundamentals

CG Oncology, Account Relationship Matchups

Pair Trading with CG Oncology,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.

Moving against CGON Stock

  0.45BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.43ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.39VTRS ViatrisPairCorr
  0.32BFRIW Biofrontera WarrantsPairCorr
The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CG Oncology, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CG Oncology,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cg Oncology, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cg Oncology, Common Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(15.87)
Revenue Per Share
0.015
Quarterly Revenue Growth
3.778
Return On Assets
(0.16)
Return On Equity
(0.20)
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.